Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 12/20 | 0.80 |
| ▸ | TLL1 | O43897 | 3/20 | 0.80 |
| ▸ | TLL2 | Q9Y6L7 | 3/20 | 0.80 |
| ▸ | MMP12 | P39900 | 5/20 | 0.72 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | FABP1 | P07148 | 1/20 | 0.33 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16898133 | 1.00 | BMP1 (0.80) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL21468693 | 1.00 | BMP1 (0.80) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL16898504 | 0.95 | BMP1 (0.72) | BMP1TLL1TLL2MMP12SUCNR1 | |
| SCHEMBL16898502 | 0.95 | BMP1 (0.72) | BMP1TLL1TLL2MMP12SUCNR1 | |
| SCHEMBL21802881 | 0.95 | BMP1 (0.72) | BMP1TLL1TLL2MMP12SUCNR1 | |
| SCHEMBL21802844 | 0.94 | BMP1 (0.72) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL16897998 | 0.94 | BMP1 (0.72) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL16897997 | 0.94 | BMP1 (0.72) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL16898228 | 0.94 | BMP1 (0.72) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL16898224 | 0.94 | BMP1 (0.72) | BMP1TLL1TLL2MMP12C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-03-26 | — | — | US | claimed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | claimed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | claimed |
| EP-3092233-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-11-16 | — | — | EP | claimed |
| WO-2015104684-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-07-16 | — | — | WO | claimed |
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-03-26 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| EP-3092233-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015104684-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | BMP1 1/4885TLL1 6/4885TLL2 11/4885 |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | BMP1 1/4885TLL1 6/4885TLL2 11/4885 |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | BMP1, BMPR1A, BMPR2 | BMP1 1/4885TLL1 6/4885TLL2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.